Chromatin Helicase CHD6 Establishes Pro-inflammatory Enhancers and is a Synthetic Lethal Target in FH-Deficient Renal Cell Carcinoma.

Juan Jin,Jun Luo,Xiaodong Jin,Kiat Shenq Lim,Yang He,Jiawei Ding,Yan Shen,Yuchen Hou,Hanqing Liu,Xiaoyu Zhu,Jing Zhao,Wenjie Zhou,Hai Huang,Yi Gao,Jun Xiao,Hongchao He,Qunyi Li,Lianxin Liu,Li Chen,Qiang He,Chuanjie Zhang
DOI: https://doi.org/10.1158/0008-5472.can-24-0787
IF: 11.2
2024-01-01
Cancer Research
Abstract:Fumarate hydratase (FH) deficiency causes hereditary leiomyomatosis and renal cell carcinoma (RCC). FH-deficient tumors lack effective therapeutic options. Here, we utilized an epigenetic-focused single-guide RNA library to elucidate potential drug targets in FH-deficient tumors. The screen identified chromodomain helicase DNA binding protein 6 (CHD6) as an essential regulator of the growth of FH-mutated RCC. Mechanically, FH loss induced fumarate-mediated succinylation and inactivation of KEAP1, blocking subsequent ubiquitin-proteasome degradation of CHD6. Stabilized CHD6 formed a complex with p65 to establish pro-inflammatory enhancers and thereby regulate NF-κB-mediated transcription. Moreover, CHD6 recruited mSWI/SNF ATPases to maintain chromatin accessibility at CHD6-bound enhancers. The PROTAC degrader of SMARCA2/4 AU-15330 effectively abolished structures of cis-regulatory elements bound by CHD6 and suppressed the growth of FH-mutated, but not FH-intact, RCC in vivo. Collectively, these data indicate that CHD6 is a molecular bridge between FH deficiency and pro-inflammatory enhancers assembly that endows FH-deficient tumors with epigenetic vulnerabilities.
What problem does this paper attempt to address?